Feb 26, 2021 / 02:00PM GMT
Operator
Greetings, and welcome to Y-mAbs' Fourth Quarter and Full Year 2020 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Thomas Gad, Chairman of Y-mAbs. Thank you, sir. You may begin.
Thomas Gad - Y-mAbs Therapeutics, Inc. - Founder, Chairman, President and Head of Business Development & Strategy
Thank you, and thank you, everyone. Good morning, and thank you for joining us today. So 2020 was the year that we believe was truly transformational for Y-mAbs as we became a commercial stage company. We've made significant progress on executing our strategy and expanding significantly on our 3 pillars of business: first, our leading monoclonal antibodies, DANYELZA and omburtamab; second, our bispecific compounds under the Y-BICLONE tech platform; and finally, the SADA technology platform.
As you know, we received U.S. approval for DANYELZA in primary refractory and relapsed high retinoblastoma on November 25, 2020. And from the beginning of February, we
Full Year 2020 Y-mAbs Therapeutics, Inc Earnings Call Transcript
Feb 26, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers